title: Effect of selenomethionine on N-methylnitronitrosoguanidine-induced colonic aberrant crypt foci in rats.
abstract: An association between low selenium intake and the incidence or prevalence of cancers is well known. Selenium in the form of selenomethionine supplemented in drinking water has been found to be highly effective in reducing tumour incidence and preneoplastic foci during the development of hepatocarcinogenesis in rats in our previous studies. Here, an attempt has been made to investigate whether the dose and form of selenium found to be effective during hepatocarcinogenesis is equally effective in N-methylnitronitrosoguanidine-induced colorectal carcinogenesis in terms of antioxidant defence enzyme systems, DNA chain breaks and incidences of aberrant crypt foci. Treatment with selenomethionine either on initiation or on selection/promotion, or during the entire experiment showed that selenomethionine was most effective in regulating the cellular antioxidant defence systems, DNA chain break control and reducing aberrant crypt foci in the colorectal tissues of rats. Our results also confirm that selenium is particularly effective in limiting the action of the carcinogen during the initiation phase of this colorectal carcinogenesis, just as we found with hepatocarcinogenesis in our previous studies.
authors.affiliation: University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh 160 014, India. biswajit@pu.ac.in
authors.forename: B
authors.initials: B
authors.lastname: Mukherjee
authors.forename: M
authors.initials: M
authors.lastname: Basu
authors.forename: M
authors.initials: M
authors.lastname: Chatterjee
mesh_terms: D000818:Animals; D000975:Antioxidants / Q000494:pharmacology; D002273:Carcinogens / Q000009:adverse effects* / Q000494:pharmacology; D002471:Cell Transformation, Neoplastic / Q000139:chemically induced*; D018890:Chemoprevention; D015179:Colorectal Neoplasms / Q000139:chemically induced* / Q000517:prevention & control; D004249:DNA Damage; D008297:Male; D008769:Methylnitronitrosoguanidine / Q000009:adverse effects* / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012645:Selenomethionine / Q000494:pharmacology*
chemical_list: D000975:Antioxidants; D002273:Carcinogens; D008769:Methylnitronitrosoguanidine; D012645:Selenomethionine